<!DOCTYPE html>
<html lang="" xml:lang="">
<head>

  <meta charset="utf-8" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <title>Três doses | VIGVAC - Rio de Janeiro</title>
  <meta name="description" content="Análises de efetividade vacinal contra Sars-Cov-2 no estado do Rio de Janeiro." />
  <meta name="generator" content="bookdown 0.24 and GitBook 2.6.7" />

  <meta property="og:title" content="Três doses | VIGVAC - Rio de Janeiro" />
  <meta property="og:type" content="book" />
  <meta property="og:url" content="https://filustria.github.io/vigvac_rj/" />
  <meta property="og:image" content="https://filustria.github.io/vigvac_rj/C:\Users\Adelson\Desktop\bd vacinas\relatorios\vigvac\docs\par42150-overlay.jpg" />
  <meta property="og:description" content="Análises de efetividade vacinal contra Sars-Cov-2 no estado do Rio de Janeiro." />
  <meta name="github-repo" content="rstudio/bookdown-demo" />

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="Três doses | VIGVAC - Rio de Janeiro" />
  
  <meta name="twitter:description" content="Análises de efetividade vacinal contra Sars-Cov-2 no estado do Rio de Janeiro." />
  <meta name="twitter:image" content="https://filustria.github.io/vigvac_rj/C:\Users\Adelson\Desktop\bd vacinas\relatorios\vigvac\docs\par42150-overlay.jpg" />




  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta name="apple-mobile-web-app-capable" content="yes" />
  <meta name="apple-mobile-web-app-status-bar-style" content="black" />
  
  
<link rel="prev" href="efetividade-vacinal-variante-delta.html"/>
<link rel="next" href="rascunho-artigo-delta.html"/>
<script src="libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<script src="https://cdn.jsdelivr.net/npm/fuse.js@6.4.6/dist/fuse.min.js"></script>
<link href="libs/gitbook-2.6.7/css/style.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-table.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-fontsettings.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-clipboard.css" rel="stylesheet" />








<script src="libs/accessible-code-block-0.0.1/empty-anchor.js"></script>
<link href="libs/anchor-sections-1.0.1/anchor-sections.css" rel="stylesheet" />
<script src="libs/anchor-sections-1.0.1/anchor-sections.js"></script>
<script src="libs/kePrint-0.0.1/kePrint.js"></script>
<link href="libs/lightable-0.0.1/lightable.css" rel="stylesheet" />


<style type="text/css">
code.sourceCode > span { display: inline-block; line-height: 1.25; }
code.sourceCode > span { color: inherit; text-decoration: inherit; }
code.sourceCode > span:empty { height: 1.2em; }
.sourceCode { overflow: visible; }
code.sourceCode { white-space: pre; position: relative; }
pre.sourceCode { margin: 0; }
@media screen {
div.sourceCode { overflow: auto; }
}
@media print {
code.sourceCode { white-space: pre-wrap; }
code.sourceCode > span { text-indent: -5em; padding-left: 5em; }
}
pre.numberSource code
  { counter-reset: source-line 0; }
pre.numberSource code > span
  { position: relative; left: -4em; counter-increment: source-line; }
pre.numberSource code > span > a:first-child::before
  { content: counter(source-line);
    position: relative; left: -1em; text-align: right; vertical-align: baseline;
    border: none; display: inline-block;
    -webkit-touch-callout: none; -webkit-user-select: none;
    -khtml-user-select: none; -moz-user-select: none;
    -ms-user-select: none; user-select: none;
    padding: 0 4px; width: 4em;
    color: #aaaaaa;
  }
pre.numberSource { margin-left: 3em; border-left: 1px solid #aaaaaa;  padding-left: 4px; }
div.sourceCode
  {   }
@media screen {
code.sourceCode > span > a:first-child::before { text-decoration: underline; }
}
code span.al { color: #ff0000; font-weight: bold; } /* Alert */
code span.an { color: #60a0b0; font-weight: bold; font-style: italic; } /* Annotation */
code span.at { color: #7d9029; } /* Attribute */
code span.bn { color: #40a070; } /* BaseN */
code span.bu { } /* BuiltIn */
code span.cf { color: #007020; font-weight: bold; } /* ControlFlow */
code span.ch { color: #4070a0; } /* Char */
code span.cn { color: #880000; } /* Constant */
code span.co { color: #60a0b0; font-style: italic; } /* Comment */
code span.cv { color: #60a0b0; font-weight: bold; font-style: italic; } /* CommentVar */
code span.do { color: #ba2121; font-style: italic; } /* Documentation */
code span.dt { color: #902000; } /* DataType */
code span.dv { color: #40a070; } /* DecVal */
code span.er { color: #ff0000; font-weight: bold; } /* Error */
code span.ex { } /* Extension */
code span.fl { color: #40a070; } /* Float */
code span.fu { color: #06287e; } /* Function */
code span.im { } /* Import */
code span.in { color: #60a0b0; font-weight: bold; font-style: italic; } /* Information */
code span.kw { color: #007020; font-weight: bold; } /* Keyword */
code span.op { color: #666666; } /* Operator */
code span.ot { color: #007020; } /* Other */
code span.pp { color: #bc7a00; } /* Preprocessor */
code span.sc { color: #4070a0; } /* SpecialChar */
code span.ss { color: #bb6688; } /* SpecialString */
code span.st { color: #4070a0; } /* String */
code span.va { color: #19177c; } /* Variable */
code span.vs { color: #4070a0; } /* VerbatimString */
code span.wa { color: #60a0b0; font-weight: bold; font-style: italic; } /* Warning */
</style>


<link rel="stylesheet" href="style.css" type="text/css" />
</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li><a href="./">VIGVAC Rio de Janeiro</a></li>

<li class="divider"></li>
<li class="chapter" data-level="" data-path="análises-de-efetividade-vacinal-no-estado-do-rio-de-janeiro.html"><a href="análises-de-efetividade-vacinal-no-estado-do-rio-de-janeiro.html"><i class="fa fa-check"></i>Análises de efetividade vacinal no estado do Rio de Janeiro</a></li>
<li class="chapter" data-level="" data-path="apresentação.html"><a href="apresentação.html"><i class="fa fa-check"></i>Apresentação</a><ul>
<li class="chapter" data-level="" data-path="apresentação.html"><a href="apresentação.html#formas-de-categorizar-o-status-vacinal"><i class="fa fa-check"></i>Formas de categorizar o Status Vacinal:</a></li>
<li class="chapter" data-level="" data-path="apresentação.html"><a href="apresentação.html#resultados-para-o-desfecho-pcr-positivo-para-sars-cov-2"><i class="fa fa-check"></i>Resultados para o desfecho PCR positivo para Sars-Cov-2:</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="análises-de-sobrevida.html"><a href="análises-de-sobrevida.html"><i class="fa fa-check"></i>Análises de Sobrevida</a></li>
<li class="chapter" data-level="" data-path="efetividade-vacinal-variante-delta.html"><a href="efetividade-vacinal-variante-delta.html"><i class="fa fa-check"></i>Efetividade vacinal variante DELTA</a></li>
<li class="chapter" data-level="" data-path="três-doses.html"><a href="três-doses.html"><i class="fa fa-check"></i>Três doses</a></li>
<li class="chapter" data-level="" data-path="rascunho-artigo-delta.html"><a href="rascunho-artigo-delta.html"><i class="fa fa-check"></i>Rascunho artigo Delta</a></li>
<li class="chapter" data-level="" data-path="rascunho-artigo-3-doses.html"><a href="rascunho-artigo-3-doses.html"><i class="fa fa-check"></i>Rascunho artigo 3 doses</a></li>
<li class="chapter" data-level="" data-path="análises-astrazeneca.html"><a href="análises-astrazeneca.html"><i class="fa fa-check"></i>Análises AstraZeneca</a><ul>
<li class="chapter" data-level="" data-path="análises-astrazeneca.html"><a href="análises-astrazeneca.html#síndrome-gripal"><i class="fa fa-check"></i>Síndrome Gripal</a></li>
<li class="chapter" data-level="" data-path="análises-astrazeneca.html"><a href="análises-astrazeneca.html#internação-hospitalar"><i class="fa fa-check"></i>Internação hospitalar</a></li>
<li class="chapter" data-level="" data-path="análises-astrazeneca.html"><a href="análises-astrazeneca.html#admissão-em-uti"><i class="fa fa-check"></i>Admissão em UTI</a></li>
<li class="chapter" data-level="" data-path="análises-astrazeneca.html"><a href="análises-astrazeneca.html#morte-por-sars-cov-2"><i class="fa fa-check"></i>Morte por Sars-Cov-2</a></li>
</ul></li>
<li class="divider"></li>
<li><a href="https://github.com/rstudio/bookdown" target="blank">Published with bookdown</a></li>

</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">VIGVAC - Rio de Janeiro</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="três-doses" class="section level1 unnumbered">
<h1>Três doses</h1>
<p>
 
</p>
<p><strong>AstraZeneca com reforço de Pfizer</strong></p>
<p><strong>Incidência de infecção por Sars-Cov-2 dentre aqueles que receberam ao menos duas doses de AstraZeneca MAIS reforço com qualquer imunizante</strong></p>
<table class=" lightable-paper lightable-hover" style='font-family: "Arial Narrow", arial, helvetica, sans-serif; width: auto !important; margin-left: auto; margin-right: auto;'>
<caption>
<span id="tab:unnamed-chunk-10">Table 9: </span>Incidência de casos de síndrome gripal notificados de acordo com o Status vacinal dos indivíduos que fizeram uso de Astrazeneca nas duas primeiras doses e Pfizer como dose de reforço (terceira dose). Estado do Rio de Janeiro, 2021
</caption>
<thead>
<tr>
<th style="text-align:left;">
Status vacinal
</th>
<th style="text-align:right;">
Pessoa-dia
</th>
<th style="text-align:right;">
número de eventos
</th>
<th style="text-align:right;">
incidência
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Pré-vacinado
</td>
<td style="text-align:right;">
589997620
</td>
<td style="text-align:right;">
273
</td>
<td style="text-align:right;">
0.0004627
</td>
</tr>
<tr>
<td style="text-align:left;">
1ª dose
</td>
<td style="text-align:right;">
59262396
</td>
<td style="text-align:right;">
682
</td>
<td style="text-align:right;">
0.0115081
</td>
</tr>
<tr>
<td style="text-align:left;">
1ª dose + 14 dias
</td>
<td style="text-align:right;">
379827200
</td>
<td style="text-align:right;">
1937
</td>
<td style="text-align:right;">
0.0050997
</td>
</tr>
<tr>
<td style="text-align:left;">
2ª dose
</td>
<td style="text-align:right;">
48180391
</td>
<td style="text-align:right;">
142
</td>
<td style="text-align:right;">
0.0029473
</td>
</tr>
<tr>
<td style="text-align:left;">
2ª dose + 14 dias
</td>
<td style="text-align:right;">
320577667
</td>
<td style="text-align:right;">
871
</td>
<td style="text-align:right;">
0.0027170
</td>
</tr>
<tr>
<td style="text-align:left;">
3ª dose
</td>
<td style="text-align:right;">
13804149
</td>
<td style="text-align:right;">
16
</td>
<td style="text-align:right;">
0.0011591
</td>
</tr>
</tbody>
</table>
<p>
 
</p>
<p>Modelos gerados em comparações binárias, sempre o período pré-vacinação como referência comparado com os status vacinais seguintes.</p>
<p>
 
</p>
<table class="table table-striped" style="font-size: 14px; width: auto !important; margin-right: 0; margin-left: auto">
<caption style="font-size: initial !important;">
<span id="tab:unnamed-chunk-11">Table 10: </span>Hazard Ratio (95% CI) para contrair Síndrome Gripal por SarsCov2 no estado do Rio de Janeiro, de acordo com o estado vacinal dos indivíduos imunizados com duas doses de AstraZeneca + dose de reforço com imunizante Pfizer entre Janeiro a Novembro de 2021.
</caption>
<thead>
<tr>
<th style="text-align:left;">
Status vacinal
</th>
<th style="text-align:left;">
Hazard Ratio (95% CI)
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
1ª dose
</td>
<td style="text-align:left;">
1.11 (1.09; 1.14)
</td>
</tr>
<tr>
<td style="text-align:left;">
1ª dose + 14 dias
</td>
<td style="text-align:left;">
0.67 (0.66; 0.68)
</td>
</tr>
<tr>
<td style="text-align:left;">
2ª dose
</td>
<td style="text-align:left;">
0.88 (0.86; 0.9)
</td>
</tr>
<tr>
<td style="text-align:left;">
2ª dose + 14 dias
</td>
<td style="text-align:left;">
0.42 (0.41; 0.42)
</td>
</tr>
<tr>
<td style="text-align:left;">
3ª dose
</td>
<td style="text-align:left;">
0.23 (0.21; 0.25)
</td>
</tr>
</tbody>
<tfoot>
<tr>
<td style="padding: 0; border:0;" colspan="100%">
<sup>*</sup> Porcentagem: Porcentagem da população positiva no momento da vacina
</td>
</tr>
<tr>
<td style="padding: 0; border:0;" colspan="100%">
<sup>†</sup> Valor de referência é não ter tomado nenhuma dose da vacina.
</td>
</tr>
<tr>
<td style="padding: 0; border:0;" colspan="100%">
<sup>‡</sup> Todos os modelos de Hazard proporcionais foram ajustados por sexo, idade do indivíduo e pela porcentagem da população positiva para COVID-19 no momento da aplicação da vacina.
</td>
</tr>
</tfoot>
</table>
<p>
 
</p>
<p><strong>Tabela agregando informações de risco absoluto e Hazard Ratios (ainda usando Cox)</strong></p>
<table class=" lightable-paper lightable-hover" style='font-family: "Arial Narrow", arial, helvetica, sans-serif; width: auto !important; margin-left: auto; margin-right: auto;'>
<caption>
<span id="tab:unnamed-chunk-12">Table 11: </span>Risco absoluto e Hazard Ratio (95% CI) para contrair Síndrome Gripal por SarsCov2 no estado do Rio de Janeiro, de acordo com o estado vacinal dos indivíduos imunizados com duas doses de AstraZeneca + dose de reforço por qualquer imunizante entre Janeiro a Novembro de 2021. Valor de referência é não ter tomado nenhuma dose da vacina.
</caption>
<thead>
<tr>
<th style="text-align:left;">
Status vacinal
</th>
<th style="text-align:right;">
Pessoa-dia
</th>
<th style="text-align:right;">
número de eventos
</th>
<th style="text-align:right;">
incidência
</th>
<th style="text-align:left;">
Hazard Ratio (95% CI)
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Pré-vacinado
</td>
<td style="text-align:right;">
589997620
</td>
<td style="text-align:right;">
273
</td>
<td style="text-align:right;">
0.0004627
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
1ª dose
</td>
<td style="text-align:right;">
59262396
</td>
<td style="text-align:right;">
682
</td>
<td style="text-align:right;">
0.0115081
</td>
<td style="text-align:left;">
1.11 (1.09; 1.14)
</td>
</tr>
<tr>
<td style="text-align:left;">
1ª dose + 14 dias
</td>
<td style="text-align:right;">
379827200
</td>
<td style="text-align:right;">
1937
</td>
<td style="text-align:right;">
0.0050997
</td>
<td style="text-align:left;">
0.67 (0.66; 0.68)
</td>
</tr>
<tr>
<td style="text-align:left;">
2ª dose
</td>
<td style="text-align:right;">
48180391
</td>
<td style="text-align:right;">
142
</td>
<td style="text-align:right;">
0.0029473
</td>
<td style="text-align:left;">
0.88 (0.86; 0.9)
</td>
</tr>
<tr>
<td style="text-align:left;">
2ª dose + 14 dias
</td>
<td style="text-align:right;">
320577667
</td>
<td style="text-align:right;">
871
</td>
<td style="text-align:right;">
0.0027170
</td>
<td style="text-align:left;">
0.42 (0.41; 0.42)
</td>
</tr>
<tr>
<td style="text-align:left;">
3ª dose
</td>
<td style="text-align:right;">
13804149
</td>
<td style="text-align:right;">
16
</td>
<td style="text-align:right;">
0.0011591
</td>
<td style="text-align:left;">
0.23 (0.21; 0.25)
</td>
</tr>
</tbody>
</table>
<p>
 
</p>
<p><strong>Análises estratificadas por idade</strong></p>
<p>Aqui os mesmos modelos de Cox foram gerados com o Status Vacinal como variável categórica em um único modelo, ajustados pela porcentagem da população positiva para COVID-19 no momento da aplicação da vacina, idade e sexo do indivíduo. Cada coluna representa um modelo para cada faixa etária.</p>
<p>
 
</p>
<table class=" lightable-paper" style='font-size: 11px; font-family: "Arial Narrow", arial, helvetica, sans-serif; margin-right: 0; margin-left: auto'>
<caption style="font-size: initial !important;">
<span id="tab:unnamed-chunk-13">Table 12: </span>Hazard Ratio (95% CI) para contrair Síndrome Gripal por SarsCov2 no estado do Rio de Janeiro, de acordo com o estado vacinal dos indivíduos imunizados com duas doses de AstraZeneca + dose de reforço com imunizante Pfizer entre Janeiro a Novembro de 2021.
</caption>
<thead>
<tr>
<th style="text-align:left;">
Status vacinal
</th>
<th style="text-align:left;">
All ages
</th>
<th style="text-align:left;">
18 - 30
</th>
<th style="text-align:left;">
30 - 40
</th>
<th style="text-align:left;">
40 - 50
</th>
<th style="text-align:left;">
50 - 60
</th>
<th style="text-align:left;">
60 - 70
</th>
<th style="text-align:left;">
&gt; 70
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
1ª dose
</td>
<td style="text-align:left;">
0.81 (0.8; 0.83)
</td>
<td style="text-align:left;">
0.8 (0.76; 0.84)
</td>
<td style="text-align:left;">
0.8 (0.77; 0.84)
</td>
<td style="text-align:left;">
0.84 (0.81; 0.87)
</td>
<td style="text-align:left;">
0.8 (0.78; 0.83)
</td>
<td style="text-align:left;">
0.81 (0.78; 0.85)
</td>
<td style="text-align:left;">
0.87 (0.79; 0.96)
</td>
</tr>
<tr>
<td style="text-align:left;">
1ª dose + 14 dias
</td>
<td style="text-align:left;">
0.65 (0.65; 0.66)
</td>
<td style="text-align:left;">
0.72 (0.7; 0.74)
</td>
<td style="text-align:left;">
0.67 (0.65; 0.68)
</td>
<td style="text-align:left;">
0.68 (0.66; 0.69)
</td>
<td style="text-align:left;">
0.69 (0.68; 0.7)
</td>
<td style="text-align:left;">
0.59 (0.57; 0.6)
</td>
<td style="text-align:left;">
0.5 (0.48; 0.53)
</td>
</tr>
<tr>
<td style="text-align:left;">
2ª dose
</td>
<td style="text-align:left;">
0.62 (0.61; 0.64)
</td>
<td style="text-align:left;">
0.73 (0.68; 0.78)
</td>
<td style="text-align:left;">
0.62 (0.59; 0.66)
</td>
<td style="text-align:left;">
0.66 (0.63; 0.69)
</td>
<td style="text-align:left;">
0.63 (0.61; 0.66)
</td>
<td style="text-align:left;">
0.51 (0.48; 0.54)
</td>
<td style="text-align:left;">
0.56 (0.5; 0.63)
</td>
</tr>
<tr>
<td style="text-align:left;">
2ª dose + 14 dias
</td>
<td style="text-align:left;">
0.4 (0.39; 0.4)
</td>
<td style="text-align:left;">
0.47 (0.46; 0.49)
</td>
<td style="text-align:left;">
0.41 (0.4; 0.42)
</td>
<td style="text-align:left;">
0.37 (0.36; 0.38)
</td>
<td style="text-align:left;">
0.36 (0.35; 0.36)
</td>
<td style="text-align:left;">
0.46 (0.45; 0.47)
</td>
<td style="text-align:left;">
0.49 (0.46; 0.51)
</td>
</tr>
<tr>
<td style="text-align:left;">
3ª dose
</td>
<td style="text-align:left;">
0.16 (0.15; 0.18)
</td>
<td style="text-align:left;">
0.35 (0.23; 0.53)
</td>
<td style="text-align:left;">
0.29 (0.21; 0.4)
</td>
<td style="text-align:left;">
0.26 (0.18; 0.36)
</td>
<td style="text-align:left;">
0.16 (0.12; 0.21)
</td>
<td style="text-align:left;">
0.13 (0.11; 0.15)
</td>
<td style="text-align:left;">
0.16 (0.14; 0.19)
</td>
</tr>
<tr>
<td style="text-align:left;">
Idade
</td>
<td style="text-align:left;">
0.99 (0.99; 0.99)
</td>
<td style="text-align:left;">
1.02 (1.02; 1.02)
</td>
<td style="text-align:left;">
1 (0.99; 1)
</td>
<td style="text-align:left;">
0.99 (0.98; 0.99)
</td>
<td style="text-align:left;">
0.97 (0.97; 0.98)
</td>
<td style="text-align:left;">
1.03 (1.03; 1.04)
</td>
<td style="text-align:left;">
0.97 (0.97; 0.97)
</td>
</tr>
<tr>
<td style="text-align:left;">
Porcentagem
</td>
<td style="text-align:left;">
1.11 (1.11; 1.12)
</td>
<td style="text-align:left;">
1.14 (1.13; 1.14)
</td>
<td style="text-align:left;">
1.14 (1.13; 1.14)
</td>
<td style="text-align:left;">
1.12 (1.11; 1.12)
</td>
<td style="text-align:left;">
1.11 (1.11; 1.11)
</td>
<td style="text-align:left;">
1.1 (1.09; 1.1)
</td>
<td style="text-align:left;">
1.12 (1.11; 1.12)
</td>
</tr>
<tr>
<td style="text-align:left;">
Sexo
</td>
<td style="text-align:left;">
0.82 (0.81; 0.82)
</td>
<td style="text-align:left;">
0.69 (0.67; 0.7)
</td>
<td style="text-align:left;">
0.81 (0.8; 0.82)
</td>
<td style="text-align:left;">
0.82 (0.81; 0.84)
</td>
<td style="text-align:left;">
0.84 (0.83; 0.85)
</td>
<td style="text-align:left;">
0.86 (0.84; 0.87)
</td>
<td style="text-align:left;">
1.16 (1.12; 1.21)
</td>
</tr>
</tbody>
<tfoot>
<tr>
<td style="padding: 0; border:0;" colspan="100%">
<sup>*</sup> Porcentagem: Porcentagem da população positiva no momento da vacina
</td>
</tr>
<tr>
<td style="padding: 0; border:0;" colspan="100%">
<sup>†</sup> Valor de referência é não ter tomado nenhuma dose da vacina.
</td>
</tr>
<tr>
<td style="padding: 0; border:0;" colspan="100%">
<sup>‡</sup> Todos os modelos de Hazard proporcionais foram ajustados por sexo, idade do indivíduo e pela porcentagem da população positiva para COVID-19 no momento da aplicação da vacina.
</td>
</tr>
</tfoot>
</table>
<p>
 
</p>
<p><strong>Modelos frailty</strong></p>
<p>
 
</p>
<table class=" lightable-paper" style='font-size: 12px; font-family: "Arial Narrow", arial, helvetica, sans-serif; margin-left: auto; margin-right: auto;'>
<caption style="font-size: initial !important;">
<span id="tab:unnamed-chunk-14">Table 13: </span>Modelos de hazard proporcionais entre indivíduos totalmente vacinados (14 dias após a segunda dose de AstraZeneca) versus não vacinados (nenhuma dose) utilizando clusterização com Frailty para contrair Síndrome Gripal por SarsCov2 no estado do Rio de Janeiro entre Janeiro a Novembro de 2021.
</caption>
<thead>
<tr>
<th style="text-align:left;">
Modelos
</th>
<th style="text-align:left;">
Hazard Ratio (IC 95%)
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Full - tudo (sem frailty)
</td>
<td style="text-align:left;">
0.4 (0.39; 0.4)
</td>
</tr>
<tr>
<td style="text-align:left;">
Full - sample 5 (sem frailty)
</td>
<td style="text-align:left;">
0.41 (0.4; 0.41)
</td>
</tr>
<tr>
<td style="text-align:left;">
Full - sample 5
</td>
<td style="text-align:left;">
0.51 (0.46; 0.56)
</td>
</tr>
<tr>
<td style="text-align:left;">
Full - sample 4
</td>
<td style="text-align:left;">
0.46 (0.42; 0.51)
</td>
</tr>
<tr>
<td style="text-align:left;">
Full - sample 3
</td>
<td style="text-align:left;">
0.44 (0.4; 0.49)
</td>
</tr>
<tr>
<td style="text-align:left;">
Full - sample 2
</td>
<td style="text-align:left;">
0.46 (0.41; 0.51)
</td>
</tr>
<tr>
<td style="text-align:left;">
Full - sample 1
</td>
<td style="text-align:left;">
0.5 (0.45; 0.55)
</td>
</tr>
</tbody>
<tfoot>
<tr>
<td style="padding: 0; border:0;" colspan="100%">
<sup>*</sup> Modelos frailty agregando dados agrupados por ID de indivíduos.
</td>
</tr>
<tr>
<td style="padding: 0; border:0;" colspan="100%">
<sup>†</sup> Valor de referência é não ter tomado nenhuma dose da vacina.
</td>
</tr>
<tr>
<td style="padding: 0; border:0;" colspan="100%">
<sup>‡</sup> Todos os modelos de Hazard proporcionais foram ajustados por sexo, idade do indivíduo e pela porcentagem da população positiva para COVID-19 no momento da aplicação da vacina.
</td>
</tr>
</tfoot>
</table>
<p>
 
</p>
<p><strong>Internações hospitalares</strong></p>
<table class=" lightable-paper" style='font-size: 12px; font-family: "Arial Narrow", arial, helvetica, sans-serif; margin-left: auto; margin-right: auto;'>
<caption style="font-size: initial !important;">
<span id="tab:unnamed-chunk-15">Table 14: </span>Hazard Ratio (95% CI) para Internação Hospitalar por SarsCov2 no estado do Rio de Janeiro, de acordo com o estado vacinal dos indivíduos imunizados com duas doses de AstraZeneca + dose de reforço por imunizante Pfizer entre Janeiro a Novembro de 2021. Valor de referência é não ter tomado nenhuma dose da vacina. Modelo de Cox ajustado por sexo, idade e tamanho da população no local de domicílio
</caption>
<thead>
<tr>
<th style="text-align:left;">
Status vacinal
</th>
<th style="text-align:left;">
All ages
</th>
<th style="text-align:left;">
18 - 30 years-old
</th>
<th style="text-align:left;">
30 - 40 years-old
</th>
<th style="text-align:left;">
40 - 50 years-old
</th>
<th style="text-align:left;">
50 - 60 years-old
</th>
<th style="text-align:left;">
60 - 70 years-old
</th>
<th style="text-align:left;">
older than 70 years-old
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
1ª dose
</td>
<td style="text-align:left;">
1.75 (1.65; 1.85)
</td>
<td style="text-align:left;">
1.28 (0.89; 1.85)
</td>
<td style="text-align:left;">
1.66 (1.34; 2.04)
</td>
<td style="text-align:left;">
2.09 (1.8; 2.43)
</td>
<td style="text-align:left;">
2.02 (1.82; 2.24)
</td>
<td style="text-align:left;">
1.79 (1.59; 2.01)
</td>
<td style="text-align:left;">
1.18 (1.01; 1.37)
</td>
</tr>
<tr>
<td style="text-align:left;">
1ª dose + 14 dias
</td>
<td style="text-align:left;">
0.64 (0.62; 0.66)
</td>
<td style="text-align:left;">
0.46 (0.37; 0.56)
</td>
<td style="text-align:left;">
0.43 (0.39; 0.48)
</td>
<td style="text-align:left;">
0.5 (0.46; 0.55)
</td>
<td style="text-align:left;">
0.72 (0.68; 0.76)
</td>
<td style="text-align:left;">
0.68 (0.64; 0.73)
</td>
<td style="text-align:left;">
0.86 (0.79; 0.94)
</td>
</tr>
<tr>
<td style="text-align:left;">
2ª dose
</td>
<td style="text-align:left;">
0.45 (0.4; 0.49)
</td>
<td style="text-align:left;">
0.25 (0.11; 0.54)
</td>
<td style="text-align:left;">
0.35 (0.23; 0.51)
</td>
<td style="text-align:left;">
0.32 (0.23; 0.43)
</td>
<td style="text-align:left;">
0.47 (0.4; 0.56)
</td>
<td style="text-align:left;">
0.45 (0.37; 0.55)
</td>
<td style="text-align:left;">
0.6 (0.49; 0.74)
</td>
</tr>
<tr>
<td style="text-align:left;">
2ª dose + 14 dias
</td>
<td style="text-align:left;">
0.3 (0.29; 0.32)
</td>
<td style="text-align:left;">
0.28 (0.2; 0.38)
</td>
<td style="text-align:left;">
0.13 (0.1; 0.16)
</td>
<td style="text-align:left;">
0.15 (0.13; 0.18)
</td>
<td style="text-align:left;">
0.21 (0.2; 0.24)
</td>
<td style="text-align:left;">
0.27 (0.24; 0.29)
</td>
<td style="text-align:left;">
0.65 (0.6; 0.71)
</td>
</tr>
<tr>
<td style="text-align:left;">
3ª dose
</td>
<td style="text-align:left;">
0.12 (0.1; 0.15)
</td>
<td style="text-align:left;">
0 (0; Inf)
</td>
<td style="text-align:left;">
0.23 (0.03; 1.67)
</td>
<td style="text-align:left;">
0.16 (0.02; 1.14)
</td>
<td style="text-align:left;">
0.26 (0.12; 0.57)
</td>
<td style="text-align:left;">
0.06 (0.03; 0.11)
</td>
<td style="text-align:left;">
0.15 (0.12; 0.2)
</td>
</tr>
<tr>
<td style="text-align:left;">
Idade
</td>
<td style="text-align:left;">
1.05 (1.05; 1.05)
</td>
<td style="text-align:left;">
1.09 (1.07; 1.12)
</td>
<td style="text-align:left;">
1.05 (1.04; 1.07)
</td>
<td style="text-align:left;">
1.05 (1.04; 1.06)
</td>
<td style="text-align:left;">
1.03 (1.02; 1.03)
</td>
<td style="text-align:left;">
1.15 (1.14; 1.17)
</td>
<td style="text-align:left;">
1.03 (1.02; 1.03)
</td>
</tr>
<tr>
<td style="text-align:left;">
Porcentagem da população positiva no momento da vacina
</td>
<td style="text-align:left;">
939.19 (592.51; 1488.7)
</td>
<td style="text-align:left;">
1431.73 (76.85; 26672.27)
</td>
<td style="text-align:left;">
479.78 (91.18; 2524.68)
</td>
<td style="text-align:left;">
1674.87 (559.34; 5015.19)
</td>
<td style="text-align:left;">
2111.33 (957.21; 4657)
</td>
<td style="text-align:left;">
127.89 (42.72; 382.92)
</td>
<td style="text-align:left;">
669.57 (224.51; 1996.87)
</td>
</tr>
<tr>
<td style="text-align:left;">
Sexo
</td>
<td style="text-align:left;">
1.49 (1.45; 1.52)
</td>
<td style="text-align:left;">
0.98 (0.84; 1.14)
</td>
<td style="text-align:left;">
1.62 (1.5; 1.76)
</td>
<td style="text-align:left;">
1.67 (1.57; 1.77)
</td>
<td style="text-align:left;">
1.57 (1.5; 1.65)
</td>
<td style="text-align:left;">
1.32 (1.25; 1.39)
</td>
<td style="text-align:left;">
1.46 (1.37; 1.54)
</td>
</tr>
</tbody>
<tfoot>
<tr>
<td style="padding: 0; border:0;" colspan="100%">
<sup>*</sup> Valor de referência é não ter tomado nenhuma dose da vacina.
</td>
</tr>
<tr>
<td style="padding: 0; border:0;" colspan="100%">
<sup>†</sup> Todos os modelos de Hazard proporcionais foram ajustados por sexo, idade do indivíduo e pela porcentagem da população positiva para COVID-19 no momento da aplicação da vacina.
</td>
</tr>
</tfoot>
</table>
<p>
 
</p>
<p><strong>Coronavac com reforço de Pfizer</strong></p>
<p>
 
</p>
<table class=" lightable-paper lightable-hover" style='font-family: "Arial Narrow", arial, helvetica, sans-serif; width: auto !important; margin-left: auto; margin-right: auto;'>
<caption>
<span id="tab:unnamed-chunk-16">Table 15: </span>Incidência de casos de síndrome gripal notificados de acordo com o Status vacinal dos indivíduos que fizeram uso de Coronavac nas duas primeiras doses e Pfizer como dose de reforço (terceira dose). Estado do Rio de Janeiro, 2021
</caption>
<thead>
<tr>
<th style="text-align:left;">
Status vacinal
</th>
<th style="text-align:right;">
Pessoa-dia
</th>
<th style="text-align:right;">
número de eventos
</th>
<th style="text-align:right;">
incidência
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Pré-vacinado
</td>
<td style="text-align:right;">
298564372
</td>
<td style="text-align:right;">
88780
</td>
<td style="text-align:right;">
0.2973563
</td>
</tr>
<tr>
<td style="text-align:left;">
1ª dose
</td>
<td style="text-align:right;">
34413987
</td>
<td style="text-align:right;">
10525
</td>
<td style="text-align:right;">
0.3058350
</td>
</tr>
<tr>
<td style="text-align:left;">
1ª dose + 14 dias
</td>
<td style="text-align:right;">
41687212
</td>
<td style="text-align:right;">
11014
</td>
<td style="text-align:right;">
0.2642057
</td>
</tr>
<tr>
<td style="text-align:left;">
2ª dose
</td>
<td style="text-align:right;">
34088852
</td>
<td style="text-align:right;">
6992
</td>
<td style="text-align:right;">
0.2051110
</td>
</tr>
<tr>
<td style="text-align:left;">
2ª dose + 14 dias
</td>
<td style="text-align:right;">
367270153
</td>
<td style="text-align:right;">
71130
</td>
<td style="text-align:right;">
0.1936721
</td>
</tr>
<tr>
<td style="text-align:left;">
3ª dose
</td>
<td style="text-align:right;">
37310971
</td>
<td style="text-align:right;">
1644
</td>
<td style="text-align:right;">
0.0440621
</td>
</tr>
</tbody>
</table>
<p>
 
</p>
<table class=" lightable-paper" style='font-size: 12px; font-family: "Arial Narrow", arial, helvetica, sans-serif; margin-left: auto; margin-right: auto;'>
<caption style="font-size: initial !important;">
<span id="tab:unnamed-chunk-17">Table 16: </span>Hazard Ratio (95% CI) para contrair Síndrome Gripal por SarsCov2 no estado do Rio de Janeiro, de acordo com o estado vacinal dos indivíduos imunizados com duas doses de Coronavac + dose de reforço com imunizante Pfizer entre Janeiro a Novembro de 2021. Valor de referência é não ter tomado nenhuma dose da vacina. Modelo de Cox ajustado por sexo, idade e tamanho da população no local de domicílio
</caption>
<thead>
<tr>
<th style="text-align:left;">
Status vacinal
</th>
<th style="text-align:left;">
All ages
</th>
<th style="text-align:left;">
18 - 30 years-old
</th>
<th style="text-align:left;">
30 - 40 years-old
</th>
<th style="text-align:left;">
40 - 50 years-old
</th>
<th style="text-align:left;">
50 - 60 years-old
</th>
<th style="text-align:left;">
60 - 70 years-old
</th>
<th style="text-align:left;">
older than 70 years-old
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
1ª dose
</td>
<td style="text-align:left;">
1.09 (1.07; 1.11)
</td>
<td style="text-align:left;">
1.08 (1.03; 1.13)
</td>
<td style="text-align:left;">
1.07 (1.02; 1.13)
</td>
<td style="text-align:left;">
0.89 (0.84; 0.96)
</td>
<td style="text-align:left;">
0.97 (0.88; 1.06)
</td>
<td style="text-align:left;">
1.49 (1.42; 1.56)
</td>
<td style="text-align:left;">
1.39 (1.33; 1.47)
</td>
</tr>
<tr>
<td style="text-align:left;">
1ª dose + 14 dias
</td>
<td style="text-align:left;">
0.75 (0.74; 0.76)
</td>
<td style="text-align:left;">
0.65 (0.63; 0.68)
</td>
<td style="text-align:left;">
0.77 (0.74; 0.8)
</td>
<td style="text-align:left;">
0.76 (0.72; 0.79)
</td>
<td style="text-align:left;">
0.71 (0.67; 0.75)
</td>
<td style="text-align:left;">
1.1 (1.06; 1.14)
</td>
<td style="text-align:left;">
1.09 (1.04; 1.13)
</td>
</tr>
<tr>
<td style="text-align:left;">
2ª dose
</td>
<td style="text-align:left;">
0.73 (0.71; 0.75)
</td>
<td style="text-align:left;">
0.66 (0.62; 0.71)
</td>
<td style="text-align:left;">
0.75 (0.7; 0.8)
</td>
<td style="text-align:left;">
0.79 (0.73; 0.85)
</td>
<td style="text-align:left;">
0.68 (0.61; 0.76)
</td>
<td style="text-align:left;">
0.9 (0.85; 0.95)
</td>
<td style="text-align:left;">
0.89 (0.84; 0.95)
</td>
</tr>
<tr>
<td style="text-align:left;">
2ª dose + 14 dias
</td>
<td style="text-align:left;">
0.75 (0.74; 0.76)
</td>
<td style="text-align:left;">
0.72 (0.71; 0.74)
</td>
<td style="text-align:left;">
0.71 (0.7; 0.73)
</td>
<td style="text-align:left;">
0.71 (0.69; 0.73)
</td>
<td style="text-align:left;">
0.76 (0.74; 0.79)
</td>
<td style="text-align:left;">
0.99 (0.96; 1.01)
</td>
<td style="text-align:left;">
1.06 (1.03; 1.1)
</td>
</tr>
<tr>
<td style="text-align:left;">
3ª dose
</td>
<td style="text-align:left;">
0.27 (0.26; 0.29)
</td>
<td style="text-align:left;">
0.7 (0.57; 0.85)
</td>
<td style="text-align:left;">
0.31 (0.25; 0.37)
</td>
<td style="text-align:left;">
0.35 (0.29; 0.42)
</td>
<td style="text-align:left;">
0.29 (0.23; 0.36)
</td>
<td style="text-align:left;">
0.26 (0.23; 0.28)
</td>
<td style="text-align:left;">
0.32 (0.3; 0.34)
</td>
</tr>
<tr>
<td style="text-align:left;">
Idade
</td>
<td style="text-align:left;">
0.99 (0.99; 0.99)
</td>
<td style="text-align:left;">
1.03 (1.03; 1.03)
</td>
<td style="text-align:left;">
1.01 (1.01; 1.01)
</td>
<td style="text-align:left;">
0.98 (0.98; 0.99)
</td>
<td style="text-align:left;">
0.98 (0.97; 0.98)
</td>
<td style="text-align:left;">
0.98 (0.98; 0.98)
</td>
<td style="text-align:left;">
0.99 (0.99; 1)
</td>
</tr>
<tr>
<td style="text-align:left;">
Porcentagem da população positiva no momento da vacina
</td>
<td style="text-align:left;">
1.12 (1.12; 1.13)
</td>
<td style="text-align:left;">
1.16 (1.16; 1.17)
</td>
<td style="text-align:left;">
1.15 (1.14; 1.15)
</td>
<td style="text-align:left;">
1.13 (1.13; 1.13)
</td>
<td style="text-align:left;">
1.13 (1.13; 1.14)
</td>
<td style="text-align:left;">
1.1 (1.09; 1.1)
</td>
<td style="text-align:left;">
1.1 (1.1; 1.11)
</td>
</tr>
<tr>
<td style="text-align:left;">
Sexo
</td>
<td style="text-align:left;">
0.87 (0.86; 0.87)
</td>
<td style="text-align:left;">
0.8 (0.79; 0.81)
</td>
<td style="text-align:left;">
0.79 (0.78; 0.81)
</td>
<td style="text-align:left;">
0.76 (0.74; 0.78)
</td>
<td style="text-align:left;">
0.79 (0.76; 0.82)
</td>
<td style="text-align:left;">
0.92 (0.9; 0.94)
</td>
<td style="text-align:left;">
1.17 (1.14; 1.19)
</td>
</tr>
</tbody>
</table>
<p>
 
</p>
<table class=" lightable-paper" style='font-size: 12px; font-family: "Arial Narrow", arial, helvetica, sans-serif; margin-left: auto; margin-right: auto;'>
<caption style="font-size: initial !important;">
<span id="tab:unnamed-chunk-18">Table 17: </span>frailty Models - Modelos de hazard proporcionais entre indivíduos totalmente vacinados (14 dias após a segunda dose de Coronavac) versus não vacinados (nenhuma dose) utilizando clusterização com Frailty para contrair Síndrome Gripal por SarsCov2 no estado do Rio de Janeiro entre Janeiro a Novembro de 2021.
</caption>
<thead>
<tr>
<th style="text-align:left;">
Modelos
</th>
<th style="text-align:left;">
Hazard Ratio (IC 95%)
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Full - tudo (sem frailty)
</td>
<td style="text-align:left;">
0.75 (0.74; 0.76)
</td>
</tr>
<tr>
<td style="text-align:left;">
Full - sample 5 (sem frailty)
</td>
<td style="text-align:left;">
0.76 (0.75; 0.76)
</td>
</tr>
<tr>
<td style="text-align:left;">
Full - sample 5
</td>
<td style="text-align:left;">
1.09 (0.98; 1.21)
</td>
</tr>
<tr>
<td style="text-align:left;">
Full - sample 4
</td>
<td style="text-align:left;">
0.95 (0.85; 1.06)
</td>
</tr>
<tr>
<td style="text-align:left;">
Full - sample 3
</td>
<td style="text-align:left;">
0.87 (0.78; 0.97)
</td>
</tr>
<tr>
<td style="text-align:left;">
Full - sample 2
</td>
<td style="text-align:left;">
1.07 (0.96; 1.2)
</td>
</tr>
<tr>
<td style="text-align:left;">
Full - sample 1
</td>
<td style="text-align:left;">
1.04 (0.93; 1.16)
</td>
</tr>
</tbody>
<tfoot>
<tr>
<td style="padding: 0; border:0;" colspan="100%">
<sup>*</sup> Modelos frailty agregando dados agrupados por ID de indivíduos.
</td>
</tr>
<tr>
<td style="padding: 0; border:0;" colspan="100%">
<sup>†</sup> Valor de referência é não ter tomado nenhuma dose da vacina.
</td>
</tr>
<tr>
<td style="padding: 0; border:0;" colspan="100%">
<sup>‡</sup> Todos os modelos de Hazard proporcionais foram ajustados por sexo, idade do indivíduo e pela porcentagem da população positiva para COVID-19 no momento da aplicação da vacina.
</td>
</tr>
</tfoot>
</table>
<p>
 
</p>
<p>
 
</p>
<hr />

</div>
            </section>

          </div>
        </div>
      </div>
<a href="efetividade-vacinal-variante-delta.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="rascunho-artigo-delta.html" class="navigation navigation-next " aria-label="Next page"><i class="fa fa-angle-right"></i></a>
    </div>
  </div>
<script src="libs/gitbook-2.6.7/js/app.min.js"></script>
<script src="libs/gitbook-2.6.7/js/clipboard.min.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-search.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-sharing.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-bookdown.js"></script>
<script src="libs/gitbook-2.6.7/js/jquery.highlight.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-clipboard.js"></script>
<script>
gitbook.require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"github": false,
"facebook": true,
"twitter": true,
"linkedin": false,
"weibo": false,
"instapaper": false,
"vk": false,
"whatsapp": false,
"all": ["facebook", "twitter", "linkedin", "weibo", "instapaper"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": "https://github.com/USERNAME/REPO/edit/BRANCH/05-tres.Rmd",
"text": "Edit"
},
"history": {
"link": null,
"text": null
},
"view": {
"link": null,
"text": null
},
"download": ["_main.pdf", "_main.epub"],
"search": {
"engine": "fuse",
"options": null
},
"toc": {
"collapse": "subsection"
}
});
});
</script>

</body>

</html>
